[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342203-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342203-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","different-germline-variants-in-the-xpa-gene-are-associated-with-severe-intermediate-or-mild-neurodegeneration-in-xeroderma-pigmentosum-patients","Different germline variants in the XPA gene are associated with severe, intermediate, or mild neurodegeneration in xeroderma pigmentosum patients","","Xeroderma pigmentosum (XP) is a rare autosomal recessive disorder driven by pathogenic variants in nucleotide excision repair genes (XPA to XPG) and POLH, producing a >1000-fold rise in sunlight-induced skin cancer risk. The study develops a simple neurological scoring scale for XP-A patients spanning severe, intermediate, and mild disease. Eighteen XP-A patients (1973–2023) were examined and classified at age 10 years, with DNA repair assays and sequencing linked to variant type and exon location. Results connect severe disease with nonsense/frameshift premature stop variants in exons 3 and 5, intermediate disease with an exon 4 splice variant, and mild disease with multiple exon 1/2 and exon 4/6 variant patterns, also highlighting contributions from both alleles.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/different-germline-variants-in-the-xpa-gene-are-associated-with-severe-intermediate-or-mild-neurodegeneration-in-xeroderma-pigmentosum-patients/342203/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/different-germline-variants-in-the-xpa-gene-are-associated-with-severe-intermediate-or-mild-neurodegeneration-in-xeroderma-pigmentosum-patients/342203.png","ImageObject",300,407,{"name":42,"@type":43},"Clementine","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main goal of this study on XPA in XP-A patients?","Question",{"text":63,"@type":64},"To connect different germline XPA variants with neurological disease severity by using a scoring scale and clinical classification.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were XP-A patients classified in the study?",{"text":68,"@type":64},"Eighteen XP-A patients examined from 1973 to 2023 were assessed and grouped as severe (n=8), intermediate (n=5/6), and mild (n=5/4) at age 10 years using a developed neurological scoring scale.",{"name":70,"@type":61,"acceptedAnswer":71},"Which XPA variant types and locations were associated with severe versus mild disease?",{"text":72,"@type":64},"Severe disease correlated with nonsense and frameshift premature stop codon pathogenic variants in exons 3 and 5. Mild disease correlated with frameshift and splice variants affecting exons 1–2, a splice variant creating a strong donor site in intron 4, and a large deletion spanning exon 6.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342203,1790535301,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","PLOS GENETICS  \nOPEN ACCESS  \nCitation: Sagun JP, Khan SG, Imoto K, Tamura D, Oh K-S, DiGiovanna JJ, et al. (2024) Different germline variants in the XPA gene are associated with severe, intermediate, or mild neurodegeneration in xeroderma pigmentosum patients. PLoS Genet 20(12): e1011265 . [https://](https://)[ ](https://)[doi.org/10.1371/journal.pgen.1011265](doi.org/10.1371/journal.pgen.1011265)  \n[Editor:](Editor: David Wilson)[ David Wilson](Editor: David Wilson), [Hasselt University:](Hasselt University:)[ ](Hasselt University:)Universiteit Hasselt, BELGIUM  \nReceived: April 25, 2024  \nAccepted: November 13, 2024  \nPublished: December 2, 2024  \nCopyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.  \nData Availability Statement: All data are in the manuscript and/or supporting information files.  \nFunding: This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. (All of the authors) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.  \nCompeting interests: None  \nRESEARCH ARTICLE  \nDifferent germline variants in theXPA gene are associated with severe, intermediate, or mild neurodegeneration in xeroderma pigmentosum patients  \nJeffrey P. Sagun1☯, Sikandar G. Khan1☯, Kyoko Imoto1,2☯, Deborah Tamura1, KyuSeon Oh1,3, John J. DiGiovanna1†, Kenneth H. Kraemer1 *  \n1 Laboratory of Cancer Biology and Genetics, DNA Repair Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America, 2 Nara Medical University, Kashihara, Japan, 3 Laboratory of Molecular Biology and Immunology, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, United States of America  \n☯ These authors contributed equally to this work.  \n† Deceased.  \n* [kraemerk@nih.gov](kraemerk@nih.gov)  \nAbstract  \nXeroderma pigmentosum (XP) is a rare autosomal recessive disease caused by pathogenic variants in seven nucleotide excision repair genes (XPA to XPG) and POLH involved in translesion synthesis. XP patients have a > 1000-fold increased risk for sunlight-induced skin cancers. Many Japanese XP-A patients have severe neurological symptoms due to a founder variant in intron 3 of the XPA gene. However, in the United States we found XP-A patients with milder clinical features. We developed a simple scoring scale to assess XP-A patients of varying neurological disease severity. We report 18 XP-A patients examined between 1973 and 2023 under an IRB approved natural history study. Using our scale, we classified our XP-A cohort into severe (n = 8), intermediate (n = 5), and mild (n = 5) disease groups at age 10 years. DNA repair tests demonstrated greatest reduction of DNA repair in cells from severe patients as compared to cells from mild patients. Nucleotide sequencing identified 18 germline pathogenic variants in the 273 amino acid, 6 exon-containing XPAgene. Based on patient clinical features, we associated these XPA variants to severe (n = 8), intermediate (n = 6), and mild (n = 4) clinical phenotypes in the patients. Protein structural analysis showed that nonsense and frameshift premature stop codon pathogenic variants located in exons 3 and 5 correlated with severe disease. Intermediate disease correlated with a splice variant at the last base in exon 4. Mild disease correlated with a frameshift variant in exon 1 with a predicted re-initiation in exon 2; a splice variant that created a new strong donor site in intron 4; and a large genomic deletion spanning exon 6. Our findings revealed correlations between disease severity, DNA repair capacity, and XPA variant type and location. In addition, both","cbCainjSJ18FAOlg","https://ap.wps.com/l/cbCainjSJ18FAOlg","pdf",4069559,27,"English","# Abstract\n## Clinical scoring and patient classification\n## DNA repair and sequencing results\n## Genotype-phenotype correlations","[{\"question\":\"What is the main goal of this study on XPA in XP-A patients?\",\"answer\":\"To connect different germline XPA variants with neurological disease severity by using a scoring scale and clinical classification.\"},{\"question\":\"How were XP-A patients classified in the study?\",\"answer\":\"Eighteen XP-A patients examined from 1973 to 2023 were assessed and grouped as severe (n=8), intermediate (n=5/6), and mild (n=5/4) at age 10 years using a developed neurological scoring scale.\"},{\"question\":\"Which XPA variant types and locations were associated with severe versus mild disease?\",\"answer\":\"Severe disease correlated with nonsense and frameshift premature stop codon pathogenic variants in exons 3 and 5. Mild disease correlated with frameshift and splice variants affecting exons 1–2, a splice variant creating a strong donor site in intron 4, and a large deletion spanning exon 6.\"}]","Different germline variants in the XPA gene are associated with severe, intermediate, or mild neurodegeneration in xeroderma pigmentosum patients | PDF",1790045758,68,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ee5787dddfb5ab705c8dfc24049207d.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/18b8af8c4e370183d6707593bf6abc0c.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/82bd294edfdaa572f548bc8aa41a2b43.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bb6e7890dc64c2ecd3c005aad979d550.webp",980,1268]